News

Novavax announced that Switzerland’s Federal Office of Public Health (FOPH) and France’s Haute Autorité de Santé (HAS) have expanded their recommendations for use of Nuvaxovid™(NVX-CoV2373) as a COVID-19 booster. In Switzerland, the FOPH recommends use of Nuvaxovid as a booster...

Evaxion Biotech A/S , a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies,  announces that the Company has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) for the joint...

Immix Biopharma, Inc, a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the fifteenth patient dosed with IMX-110 to-date. IMX-110 clinical trial...

HitGen Inc announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. , a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered...

Kuehne+Nagel has entered into a long-term agreement for a new airside facility strategically located in the airport zone of OR Tambo International airport, Johannesburg, South Africa – the largest and busiest airport in Africa. As part of this agreement,...

Vertex Pharmaceuticals and Entrada Therapeutics, Inc. entered a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage...

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation announced the creation of a dedicated center to enhance Emmes' legacy and depth in cell and gene therapy research. The new...